David Richards

David Richards is a life sciences executive with expertise in corporate development, team building, operations, capital structuring, research and development, program management, and intellectual property development. Mr. Richards has served as Chief Executive Officer of Clarametyx Biosiences since 2020. Prior to Clarametyx, Mr. Richards served in operational and general counsel roles for Aclipse Therapeutics, which focuses on molecular pathways that regulate cellular stress, protein misfolding and inflammation in neurodegenerative and gastrointestinal disease areas; and N8 Biosciences, Inc., which is commercializing novel small molecule antimicrobial therapeutics and device coatings that mimic naturally occurring antimicrobial peptides. Prior to these roles, Mr. Richards served in operational and legal capacities for various startups, family office funds and was an associate at a large multinational law firm Latham & Watkins LLP. Mr. Richards received a bachelor’s degree in economics from Vanderbilt University and his JD from the University of Texas School of Law.